Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Share-based Compensation (2023 - 2025)

Historic Share-based Compensation for Contineum Therapeutics (CTNM) over the last 3 years, with Q3 2025 value amounting to $2.6 million.

  • Contineum Therapeutics' Share-based Compensation rose 1213.44% to $2.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.8 million, marking a year-over-year increase of 8461.97%. This contributed to the annual value of $6.8 million for FY2024, which is 20662.46% up from last year.
  • Per Contineum Therapeutics' latest filing, its Share-based Compensation stood at $2.6 million for Q3 2025, which was up 1213.44% from $2.4 million recorded in Q2 2025.
  • In the past 5 years, Contineum Therapeutics' Share-based Compensation ranged from a high of $2.6 million in Q1 2025 and a low of $477000.0 during Q3 2023
  • Moreover, its 3-year median value for Share-based Compensation was $1.5 million (2024), whereas its average is $1.5 million.
  • In the last 5 years, Contineum Therapeutics' Share-based Compensation skyrocketed by 38029.35% in 2024 and then surged by 1213.44% in 2025.
  • Over the past 3 years, Contineum Therapeutics' Share-based Compensation (Quarter) stood at $759000.0 in 2023, then soared by 196.57% to $2.3 million in 2024, then rose by 14.13% to $2.6 million in 2025.
  • Its Share-based Compensation stands at $2.6 million for Q3 2025, versus $2.4 million for Q2 2025 and $2.6 million for Q1 2025.